Muscular response to mechanical overload in hypercholesterolemic patients treated with simvastatin: isokinetic evaluation through computerized dynamometry

Tobbert, 1988, Efficacy and long term adverse effects pattern of lovastatin, Am J Cardiol, 62, 28J, 10.1016/0002-9149(88)90004-5 Bradford, 1991, Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia, Arch Intern Med, 1515, 43, 10.1001/archinte.1991.00400010067008 Mantell, 1990, Extended clinical safety profile of lovastatin, Am J Cardiol, 66, 11b, 10.1016/0002-9149(90)90435-4 Maher, 1990, HMG CoA reductase inhibitors as lipid lowering agents: Five year experience with lovastatin and an appraisal of simvastatin and pravastatin, Q J Med, 274, 165 Simon, 1993, Simvastatin in severe primary hypercholesterolemia: Efficacy, safety, and tolerability in 595 patients over 18 weeks, Clin Cardiol, 16, 317, 10.1002/clc.4960160406 Yoshino, 1989, Two-year study on the effect of pravastatin on plasma lipoprotein and apolipoprotein concentrations in hypercholesterolemic patients, Curr Ther Res, 46, 144 Jones, 1990, Lovastatin and simvastatin prevention studies, Am J Cardiol, 66, 39B, 10.1016/0002-9149(90)90439-8 Davies, 1985 1988, Report of National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Arch Intern Med., 148, 36, 10.1001/archinte.1988.00380010040006 1993, The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, Arch Intern Med, 153, 154, 10.1001/archinte.1993.00410020010002 Friedewald, 1972, Estimation of the concentration of low density lipoprotein in plasma without use of preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 1970, German Gesellschaft für Klinische Chemie, Z Klin Chem U Klin Biochem, 8, 658 1988, Current status of blood cholesterol measurements in clinical laboratories of United States. A report from Laboratory Standardization Panel of the National Cholesterol Education Program, Clin Chem., 1, 193 Smith, 1991, HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism study, J Pharmacol Exp Ther, 257, 1225 Tikkanen, 1992, Use of HMG-CoA reductase inhibition in clinical practice, Lipid Rev, 6, 1 Roust, 1991, Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise, West J Med, 154, 198 Thompson, 1991, Effects of exercise and lovastatin on serum creatinine kinase activity, Metabolism, 40, 1333, 10.1016/0026-0495(91)90039-Y